SOPHiA GENETICS (NASDAQ:SOPH) Insider Zhenyu Xu Sells 17,000 Shares

SOPHiA GENETICS SA (NASDAQ:SOPH) insider Zhenyu Xu sold 17,000 shares of the business’s stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $7.29, for a total value of $123,930.00. Following the completion of the transaction, the insider directly owned 590,887 shares of the company’s stock, valued at approximately $4,307,566.23. This trade represents a 2.80% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Zhenyu Xu also recently made the following trade(s):

• On Wednesday, August 5th, Zhenyu Xu sold 3,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $7.00, for a total transaction of $21,000.00.
• On Tuesday, August 4th, Zhenyu Xu sold 10,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $6.92, for a total transaction of $69,200.00.
• On Monday, July 13th, Zhenyu Xu sold 4,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.70, for a total transaction of $22,800.00.
• On Monday, July 6th, Zhenyu Xu sold 7,393 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.17, for a total transaction of $38,221.81.

SOPHiA GENETICS Stock Up 15.2%

Shares of SOPHiA GENETICS stock opened at $7.71 on Friday. SOPHiA GENETICS SA has a twelve month low of $2.96 and a twelve month high of $7.86. The company has a quick ratio of 1.90, a current ratio of 2.69 and a debt-to-equity ratio of 0.58. The company’s 50 day moving average is $5.63 and its 200 day moving average is $5.15. The company has a market cap of $646.79 million, a price-to-earnings ratio of -6.70 and a beta of 0.96.

SOPHiA GENETICS (NASDAQ:SOPH) last posted its earnings results on Tuesday, August 4th. The company reported ($0.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.05). The company had revenue of $23.31 million during the quarter, compared to the consensus estimate of $21.72 million. SOPHiA GENETICS had a negative return on equity of 132.47% and a negative net margin of 93.86%. Research analysts anticipate that SOPHiA GENETICS SA will post -0.77 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Perkins Capital Management Inc. purchased a new position in shares of SOPHiA GENETICS during the 4th quarter worth $49,000. Squarepoint Ops LLC purchased a new stake in shares of SOPHiA GENETICS in the 3rd quarter worth $49,000. First Dallas Securities Inc. purchased a new stake in shares of SOPHiA GENETICS in the 1st quarter worth $50,000. Quadrature Capital Ltd purchased a new stake in shares of SOPHiA GENETICS in the 4th quarter worth $54,000. Finally, XTX Topco Ltd bought a new position in SOPHiA GENETICS in the 4th quarter worth $55,000. 31.59% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several analysts recently commented on SOPH shares. HC Wainwright lifted their price objective on SOPHiA GENETICS from $12.00 to $14.00 and gave the stock a “buy” rating in a report on Wednesday. Zacks Research raised SOPHiA GENETICS to a “hold” rating in a report on Tuesday, July 21st. BTIG Research raised their target price on SOPHiA GENETICS from $8.00 to $9.00 and gave the stock a “buy” rating in a research report on Wednesday. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of SOPHiA GENETICS in a research note on Friday, July 17th. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $10.00.

Key SOPHiA GENETICS News

Here are the key news stories impacting SOPHiA GENETICS this week:

• Positive Sentiment: BTIG Research raised its price target for SOPH from $8 to $9 while maintaining a Buy rating. The move adds to recent analyst support and reinforces the stock’s upward momentum. BTIG Research raises SOPHiA GENETICS price target
• Positive Sentiment: SOPHiA GENETICS reached a new 12-month high following the analyst upgrade, indicating strong investor demand and a favorable near-term trading reaction. SOPHiA GENETICS reaches a new 12-month high
• Positive Sentiment: HC Wainwright continues to rate SOPH Buy with a $14 price target, well above recent trading levels. Its longer-term forecast still calls for a return to profitability, including positive EPS estimates for 2029 and 2030.
• Neutral Sentiment: Chief Technology Officer Abhimanyu Verma sold 5,000 shares for approximately $34,750 under a pre-arranged Rule 10b5-1 plan. Because the sale was scheduled in advance and reduced his ownership by only 2.6%, it carries limited signaling value.
• Negative Sentiment: HC Wainwright lowered EPS estimates across several periods: Q3 2026 to $(0.13), FY2026 to $(0.77) from $(0.58), FY2027 to $(0.31) from $(0.20), and FY2028 to $(0.02) from positive $0.04. Estimates for Q1–Q4 2027 were also reduced, suggesting profitability may arrive later than previously expected.
• Negative Sentiment: The company’s latest quarterly loss of $(0.26) per share exceeded the expected $(0.21) loss, highlighting ongoing profitability pressure despite revenue exceeding expectations. SOPH remains deeply unprofitable, which could limit further gains if growth or the path to breakeven weakens.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.